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Abstract
Background: NDRG2 (N-Myc downstream-regulated gene 2) was initially cloned in our laboratory. Previous results
have shown that NDRG2 expressed differentially in normal and cancer tissues. Specifically, NDRG2 mRNA was down-
regulated or undetectable in several human cancers, and over-expression of NDRG2 inhibited the proliferation of cancer
cells. NDRG2 also exerts important functions in cell differentiation and tumor suppression. However, it remains unclear
whether NDRG2 participates in carcinogenesis of the thyroid.
Methods: In this study, we investigated the expression profile of human NDRG2 in thyroid adenomas and carcinomas,
by examining tissues from individuals with thyroid adenomas (n = 40) and carcinomas (n = 35), along with corresponding
normal tissues. Immunohistochemistry, quantitative RT-PCR and western blot methods were utilized to determine both
the protein and mRNA expression status of Ndrg2 and c-Myc.
Results: The immunostaining analysis revealed a decrease of Ndrg2 expression in thyroid carcinomas. When comparing
adenomas or carcinomas with adjacent normal tissue from the same individual, the mRNA expression level of NDRG2
was significantly decreased in thyroid carcinoma tissues, while there was little difference in adenoma tissues. This
differential expression was confirmed at the protein level by western blotting. However, there were no significant
correlations of NDRG2 expression with gender, age, different histotypes of thyroid cancers or distant metastases.
Conclusion: Our data indicates that NDRG2 may participate in thyroid carcinogenesis. This finding provides novel insight
into the important role of NDRG2 in the development of thyroid carcinomas. Future studies are needed to address
whether the down-regulation of NDRG2 is a cause or a consequence of the progression from a normal thyroid to a
carcinoma.
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Background
The well-known oncogene, MYC, was first identified as
the cellular homolog of the viral oncogene myc [1]. Sub-
sequent research showed that human cancers frequently
display amplification of c-Myc, indicating the importance
of this gene in cancer [2-4]. Expression of the c-Myc pro-
tein or the c-MYC gene is increased in a variety of human
cancers, including over 80% of mammary cancers, 70% of
colon cancers and 50% of hepatocellular carcinomas
[5,6]. As an important oncogene and transcription factor,
Myc was recognized as a dominant factor in cell cycle pro-
gression, cell differentiation, apoptosis and genomic
instability. Because Myc promotes cell proliferation and
inhibits cell differentiation [7,8], most of the target genes
that are transcriptionally repressed by Myc have the oppo-
site biological role. For example, they may inhibit cell pro-
liferation, especially in cancer cells, or initiate cell
differentiation.
Up-regulation of mouse ndrg1 was initially discovered in
N-myc knockout mice [9]. Accordingly, it was named the
'N-myc downstream-regulated gene.' The mouse ndrg fam-
ily now includes three members, ndrg1, ndrg2 and ndrg3.
Subsequently, the human NDRG  family members,
NDRG1, NDRG2, NDRG3 and NDRG4, were cloned [10-
13]. The amino acid sequence homology among human
NDRG family members is 57–65%, indicating the con-
served function of this family.
We were the first to identify human NDRG2 (AF 159092)
and demonstrated that NDRG2 was a candidate tumor
suppressor gene [10]. We also found that expression of
NDRG2 in human glioblastoma tissues was significantly
lower than in normal tissue and demonstrated that Myc
repressed human NDRG2 through a Miz-1-dependent
interaction with the core promoter of NDRG2 [14].
As a gene that is regulated downstream of Myc, NDRG2
expression has been shown to be reduced in many types
of carcinomas. Our previous data and other reports
showed that NDRG2 expression was decreased in breast
cancer, lung cancer, hepatocellular carcinoma, colon can-
cer and gliomas [10,15-17]. Furthermore, NDRG2 was
shown to be up-regulated in Alzheimer's brains [18] and
could induce the differentiation of dendritic cells [19].
Our previous results also demonstrated the increased
NDRG2 expression following the differentiation and mat-
uration of U937 and HL60 leukemia cells. These findings
implicate the important role of NDRG2 in cell growth and
differentiation [14].
In the pathogenesis of thyroid cancer, evidence indicates
that there are many genetic alterations and unique chro-
mosomal rearrangements that occur, including the
involvement of the RET-Ras-BRAF signaling cascade
[20,21]. As human NDRG2 is important in cell prolifera-
tion and differentiation, we investigated whether NDRG2
participated in the carcinogenesis of thyroid cancer. Using
immunochemistry, we first analyzed a tissue microarray
of thyroid adenomas and carcinomas. The results showed
that NDRG2 expression was significantly decreased in car-
cinomas, but was only slightly reduced in adenomas. We
also detected obvious amplification of Myc in the thyroid
cancer tissues, compared to normal tissues. This result was
confirmed through a subsequent examination of clinical
samples from patients with thyroid adenomas and carci-
nomas. Using real-time PCR and western blot analysis, we
assessed the mRNA and protein expression levels of
NDRG2 in thyroid carcinomas and adenomas.
Methods
1. Tissue microarray
Two tissue microarrays, purchased from ChaoYing Bio-
technology Co. Ltd. (CC15-11-001 and CC15-21-001),
were used in the immunochemical analysis. Each micro-
array contains 159 thyroid tissue samples, including 81
thyroid carcinomas, 38 thyroid adenomas, and 40 normal
thyroid tissues. Each thyroid tissue sample comes with
detailed information regarding the patient, including gen-
der, age and tumor histotype. Table 1 summarizes the data
regarding the samples.
2. Clinical collection of thyroid samples
A total of 35 thyroid carcinomas samples were collected.
This group was comprised of 20 papillary thyroid carcino-
mas (PTCs), eight follicular thyroid carcinomas (FTCs),
five medullary thyroid carcinomas (MTCs), and two
undifferentiated thyroid carcinomas (UTCs). Addition-
ally, 40 thyroid adenoma samples were obtained. Human
thyroid tumor tissues and their normal counterparts were
accumulated between 2006 and 2007 from patients with
thyroid tumors. They were gathered at the time of surgery
Table 1: List of various histotypes of thyroid tumor on the tissue arrays
Papillary carcinomas Follicular 
carcinomas
Medullary 
carcinomas
Undifferentiated 
carcinomas
Follicular Adenomas Normal
n = 51 n = 15 n = 8 n = 7 n = 38 n = 40
Women 41 9 6 3 33 25
M e n 1 0 6245 1 5
Age (Mean ± SD) 39.63 ± 16.07 39.37 ± 16.34 43.38 ± 16.34 43.63 ± 10.03 39.87 ± 11.46 40.78 ± 10.15BMC Cancer 2008, 8:303 http://www.biomedcentral.com/1471-2407/8/303
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from the Department of General Surgery, Tangdu Hospi-
tal and Xijing Hospital, FMMU (Xi'an, China).
The collection and use of human thyroid tissues were
approved by the Fourth Military Medical University med-
ical ethics committee. All patients provided written
informed consent.
After surgical removal, all thyroid tumor tissues were
immediately frozen in liquid nitrogen and stored at -70°C
until processing. Each tumor was scored for clinical stag-
ing based on the tumor-node-metastasis (TNM) classifica-
tion, which was introduced in 1987 by the International
Union Against Cancer. All of the samples had been
reviewed and given a final diagnosis by three different
clinical pathologists. The distribution of gender, age, his-
tological diagnosis and TNM stages for the 35 thyroid car-
cinomas is shown in Table 2.
3. Immunohistochemistry
A rabbit anti-human Ndrg2 polyclonal antibody was pre-
pared in our laboratory. A PV-6000 immunohistochemis-
try kit was purchased from Zhongshan Company (Beijing,
China). Paraffin wax and beeswax were purchased from
Leica Histowax (Germany) and Hualing Company
(Shanghai, China), respectively.
Tumor microarray paraffin blocks were cut into 4 μm sec-
tions. The sections were deparaffinized, heated at 70°C
for 2 h, washed twice for 10 min in xylene, hydrated, and
then washed twice for 3 min with phosphate-buffered
saline (PBS). The tissue microarrays were incubated with
3% hydrogen peroxide for 10 min at room temperature
and then subjected to three 3 min washes in PBS. Antigens
were retrieved in 0.01 mol/L citrate buffer (pH 6.0) by
incubating at 92–98°C for 25 min. Sections were allowed
to cool naturally to room temperature and were washed
twice for 3 min with PBS. The slides were then held in
blocking solution for 30 min at 37°C. Sections were incu-
bated with anti-Ndrg2 and anti-c-Myc polyclonal anti-
bodies (1:50) for 4 h at 37°C and then washed with PBS
three times for 3 min. Sections were incubated with HRP-
conjugated goat anti-rabbit IgG secondary antibody for 10
min at 37°C. Immunolabeling was visualized by reaction
with 3, 3'-diaminobenzidine (DAB). They were then
removed from the DAB solution upon confirmation of
color development and rinsed in PBS. Finally, the sections
were counterstained with hematoxylin, dehydrated using
graded dilutions of ethanol and coverslipped. A slide
incubated with anti-actin primary antibodies served as the
positive control, and a slide maintained in 0.01 mol/L
PBS (pH 7.4), instead of the primary antibody solution,
served as a negative control.
4. Immunohistochemistry scoring criteria
To examine the immunohistochemistry, we used the scor-
ing method of Sinicrope et al. [22]. Both the intensity and
the extent of immunological staining were analyzed semi-
quantitatively. Array fields were scored with respect to the
quantity of positive cells. Sections with no labeling or
with fewer than 5% labeled cells were scored as 0. Sections
were scored as a 1 with labeling of 5–25% of cells, as a 2
with 25–50% of cells and as a 3 with 50–75% of cells.
Finally, labeling of ≥75% of the cells was scored as a 4. The
staining intensity was scored similarly, with 0 used for
negative staining, 1 for weakly positive, 2 for moderately
positive and 3 for strongly positive. The scores for the per-
centage of positive tumor cells and for the staining inten-
sity were multiplied to generate an immunoreactive score
Table 2: List of patients with thyroid carcinomas
ID Age (yrs) Sex Histological diagnosis pTxNxMx
1 39 male PTC pT1N0M0
2 45 male PTC pT2N1M0
3 56 male PTC pT1N0M0
4 25 female PTC pT1N0M0
5 27 female PTC pT3N0M0
6 28 female PTC pT1N0M0
7 30 female PTC pT1N0M0
8 31 female PTC pT2N0M0
9 32 female PTC pT1N0M0
10 36 female PTC pT2N0M0
11 36 female PTC pT1N0M0
12 38 female PTC pT1N0M0
13 39 female PTC pT2N0M0
14 40 female PTC pT4aN1M0
15 48 female PTC pT3N0M0
16 50 female PTC pT4aN1M1
17 52 female PTC pT1N0M0
18 55 female PTC pT1N0M0
19 59 female PTC pT1N0M0
20 67 female PTC pT1N0M0
21 67 male FTC pT1N0M0
22 27 female FTC pT2N0M0
23 38 female FTC pT1N0M0
24 40 female FTC pT1N0M0
25 45 female FTC pT1N0MX
26 56 female FTC pT4aN1M1
27 76 female FTC pT3N0M0
28 65 female FTC pT1N0M0
29 49 male UTC pT4aN1M0
30 59 male UTC pT4aN0M0
31 57 male MTC pT1N0M0
32 65 male MTC pT2N0M0
33 38 female MTC pT1N0M0
34 49 female MTC pT2N1M0
35 74 female MTC pT2N0M0
a pT, pathologic tumor stage; N, nodal involvement; M, distant 
metastasis at the time of surgery.
PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; 
UTC, undifferentiated thyroid carcinoma; MTC, medullary thyroid 
carcinoma.BMC Cancer 2008, 8:303 http://www.biomedcentral.com/1471-2407/8/303
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for each specimen. The product of the quantity and inten-
sity scores were calculated such that a final score of 0 indi-
cated no expression, 0–4 indicated weak expression, 4–8
indicated moderate expression and 8–12 indicated strong
expression. Each sample was examined separately and
scored by two pathologists. Cases with discrepancies in
the scores were discussed to reach a consensus.
5. RNA isolation and quantitative RT-PCR analysis
The tissue had been frozen in liquid nitrogen and stored
at -80°C. Total RNA was extracted and purified from each
sample, using the TRIzol reagent (Invitrogen). After quan-
tification, total RNA (2 μg) was reverse-transcribed with
reverse transcriptase (Promega, WI), according to the
manufacturer's instructions. All PCR experiments were
performed with Taq polymerase (Promega, WI). Quanti-
tative RT-PCR was performed on a Prism 7500 real-time
PCR system (Applied Biosystems) in Universal Mastermix
(Applied Biosystems) to amplify NDRG2 and c-MYC.
Primers were designed using the Primer Express Software
(ABI, Foster City, CA). SYBR green (TAKARA) was used in
each reaction for detection. The NDRG2 primers were 5'-
GCCCAGCGATCCTTACCTACC-3' and 5'-GGCTGCCCAA
TCCATCCAACC-3'. The c-MYC primers were 5'-GGAG-
GAACAAGAAGATGAGGAAG-3' and 5'-AGGACCAGTGG
GCTGTGAGG-3'. The GAPDH  primers were 5'-GCCT-
CAAGATCATCAGCAAT-3' and 5'-AGGTCCACCACTGAC
ACGTT-3'.  NDRG2, c-MYC  and  GAPDH  mRNAs were
quantified separately in triplicate.
Each sample was used in a single reaction, which was
incubated at 95°C for 10 s, followed by 40 cycles of 95°C
for 5 s and 60°C for 34 s. Fluorescent data were converted
into cycle threshold (CT) measurements, using the ABI
Prism 7500 SDS system software.
6. Cell lysis and western blot analysis
Cells from each tissue sample were washed twice with ice-
cold phosphate-buffered saline. Cells were collected and
lysed with lysis buffer (50 mM Tris, pH 7.5, 150 mM
NaCl, 1 mM MgCl2, 0.5% NP-40, 0.1 mM PMSF and pro-
tease inhibitor cocktail). Whole protein lysate (50 μg,
measured using the BCA protein assay, Pierce, Rockford,
IL) was loaded onto 12% SDS polyacrylamide gels for
electrophoresis and transferred to Hybond ECL nitrocellu-
lose membranes (Amersham Biosciences, Piscataway, NJ).
The membranes were blocked with 5% fat free milk in
Tris-buffered saline containing 0.05% Tween-20 and incu-
bated with each primary antibody (Ab) overnight at 4°C.
The following primary antibodies were used: anti-Ndrg2
goat polyclonal (Santa Cruz Biotechnology, Santa Cruz,
CA), anti-c-Myc rabbit polyclonal (sc-764; Santa Cruz Bio-
technology) and anti-β-actin rabbit polyclonal (Boster,
Wu Han, China). Finally, to detect the primary antibody,
blots were incubated with horseradish peroxidase-conju-
gated secondary antibodies (1:4000 dilution; Santa Cruz
Biotechnology) for at least 1 h at room temperature. The
ECL detection solutions (Pierce) were then applied.
Scanned images were quantified using the Kodak Digital
Science 1D software (Kodak, New Haven, CT).
7. Statistical analysis
For real-time PCR and immunostaining assays, significant
differences across groups were analyzed using the Kruskal-
Wallis tests and the Wilcoxon rank sum tests with the Bon-
ferroni's correction for pairwise comparisons. Compari-
sons between cancer (adenoma) tissues and tissue
adjacent to the cancer (adenoma) were performed using
the Wilcoxon signed-rank test. The correlation analysis
between RNA and protein was calculated using the Spear-
man correlation coefficient, and this analysis was used as
well for Myc and NDRG2. All tests were two-tailed, and
statistical significance was set at p < 0.05.
Results
1. Differential expression of Ndrg2 in thyroid carcinomas 
and normal tissues
Because Ndrg2 expression is decreased in many types of
cancer tissues [10,15], a preliminary analysis on Ndrg2
expression in thyroid tumors was performed using a tissue
microarray. With immunostaining analysis, a different
expression pattern of Ndrg2 was detected in thyroid carci-
nomas and normal tissues (Fig. 1A). By pairwise compar-
ison with Bonferroni's correction, we found a statistically
significant increase of Ndrg2 expression in normal thyroid
compared to carcinomas (Fig. 1B). We also noted that
Ndrg2 expression decreased slightly in thyroid adenomas,
though the difference was not statistically significant (p >
0.1).
Our previous results showed that Ndrg2 was primarily
localized in the cytoplasm of mouse tissues [23]. In
human thyroid tissue, we also detected predominantly
cytoplasmic localization of Ndrg2 in both normal and
adenoma tissues (Fig. 1C). Substitution of the primary
antibody with a control serum abolished immunostain-
ing in the tissue microarray (data not shown).
We confirmed that Myc could transcriptionally repress the
expression of human NDRG2 during the processes of cell
proliferation and differentiation [14]. We also examined
the expression level of c-Myc in the thyroid tissue micro-
array. Interestingly, the results were similar to those
observed in gliomas [10], with amplification of Myc in
thyroid cancers, compared to normal tissues (Fig. 1A, C).
2. Decreased Ndrg2 protein level in clinical samples of 
thyroid tissue
The expression profiles of Ndrg2 in the microarray of thy-
roid tissues suggested an important role for Ndrg2 in thy-BMC Cancer 2008, 8:303 http://www.biomedcentral.com/1471-2407/8/303
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Differential expression of Ndrg2 and c-Myc in thyroid carcinoma, adenoma and normal tissue Figure 1
Differential expression of Ndrg2 and c-Myc in thyroid carcinoma, adenoma and normal tissue. (A) Immunohisto-
chemical analysis of Ndrg2 and c-Myc in thyroid cancer, adenoma and normal tissues. (B) Ndrg2 expression was higher in nor-
mal tissue than the carcinomas (p < 0.05). The amplification of c-Myc was more abundant in cancers than in normal thyroid 
tissue. (C) Analysis of Ndrg2 localization in thyroid cells. The brown immunostaining indicates the cytoplasmic localization of 
Ndrg2.BMC Cancer 2008, 8:303 http://www.biomedcentral.com/1471-2407/8/303
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roid carcinogenesis. We thus wanted to analyze the
expression level of Ndrg2 protein in adjacent normal and
neoplastic thyroid tissues from human patients to con-
firm the results. The thyroid cancer and corresponding
normal samples on the microarray were not paired well.
Therefore, we had extra incentive to collect paired thyroid
carcinomas (n = 35), adenomas (n = 40) and their normal
counterparts. We then examined the expression profiles of
Ndrg2 and c-Myc by immunohistochemistry and western
blotting.
The immunostaining results demonstrated the same pat-
tern of expression as the microarray (data not shown).
Furthermore, the protein levels of Ndrg2 and c-Myc were
analyzed using western blotting. Expression of Ndrg2 was
reduced in thyroid cancers, compared to normal tissues
(Fig. 2), consistent with the microarray analysis. We also
observed reduced expression of Ndrg2 protein in a few
samples of thyroid adenomas. Compared with the corre-
sponding normal tissues, positive amplification of c-Myc
was detected in the thyroid cancers, while little c-Myc was
seen in the thyroid adenomas. These results suggest that
decreased expression of Ndrg2 correlates with thyroid
cancer.
3. Reduced NDRG2 mRNA level in thyroid cancer
Based on the detection of Ndrg2 protein expression in
thyroid cancer tissues, real-time RT-PCR was used to
investigate  NDRG2 mRNA levels in thyroid adenomas
and carcinomas. The data showed that expression of
NDRG2 mRNA in thyroid cancer tissues was lower than in
the adjacent cancer group (Fig. 3A). Expression of GAPDH
was used for normalization. However, the expression of c-
Myc was extremely high in cancer tissues. Upon examin-
ing these levels of expression, we noted a tendency
towards decreased NDRG2 expression with increasing c-
Myc expression in thyroid cancer (Fig. 3A). There was a
negative correlation between Myc and NDRG2 expression
levels in the thyroid carcinomas (r = -0.336, p = 0.048).
Further analysis of NDRG2 and c-Myc expression in ade-
nomas and the adjacent tissue showed no significant dif-
ferences. Moreover, we analyzed the association of
NDRG2 expression with the patient's gender and age.
Dividing all of the thyroid tissue samples into male and
female groups revealed mostly balanced levels of NDRG2
expression for both groups, but with slightly lower
NDRG2 expression in the females (Table 3). Furthermore,
NDRG2 expression was slightly decreased in the group of
patients who were over 45 years, compared to the group
younger than 45 (Table 3). However, this difference was
not statistically significant. Thus, expression of NDRG2
did not correlate with gender or age (Fig. 3B). Finally,
potential correlations between NDRG2 mRNA expression,
the different histotypes of thyroid cancers and distant
metastases were investigated. We found no significant dif-
ferences between the groups.
Discussion
The annual occurrence of thyroid cancer varies considera-
bly in different regions, ranging from 1.2–2.6 per 100,000
individuals in males and from 2.0–3.8 per 100,000 in
females. Several reports have shown that the incidence of
thyroid cancer has increased in recent years [20,24]. With
better diagnostic methods, there is also more detection of
thyroid cancers at earlier stages. However, some thyroid
cancer still develops into advanced stages with spreading
and metastasis. It remains unclear how normal thyroid
tissue develops into cancerous tissue.
In the present study, we demonstrated that the mRNA and
protein expression levels of NDRG2 were decreased in
thyroid cancers, compared to normal tissues. We first
observed the different expression profiles of Ndrg2 in a
thyroid tissue array using immunohistochemistry, and we
found low expression levels of Ndrg2 in the carcinomas,
compared with normal tissue. In accord with our previous
finding that Myc can transcriptionally repress human
NDRG2, we also detected amplification of c-Myc in thy-
roid cancers, consistent with findings in other cancers
[5,6].
To examine Ndrg2 at the levels of mRNA and protein, we
analyzed a collection of clinical samples, including 35
thyroid cancers and 40 adenomas. Our results showed sig-
Expression of Ndrg2 and c-Myc protein by Western blot  analysis in cancer, adenoma and normal thyroid tissues Figure 2
Expression of Ndrg2 and c-Myc protein by Western 
blot analysis in cancer, adenoma and normal thyroid 
tissues. Three paired thyroid cancers and the normal coun-
terpart, along with three thyroid adenomas and the normal 
counterpart were analyzed by Western blotting. Anti-Ndrg2 
and anti-c-Myc antibodies were used, while an anti-β-actin 
antibody was the control.BMC Cancer 2008, 8:303 http://www.biomedcentral.com/1471-2407/8/303
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Reduced NDRG2 and increased c-MYC mRNA level in thyroid cancers Figure 3
Reduced NDRG2 and increased c-MYC mRNA level in thyroid cancers. (A) Real-time PCR was used to detect differ-
ences in NDRG2 and c-MYC RNA levels in thyroid tissues. The mean values of NDRG2 and c-MYC mRNA levels were calculated 
after normalization to the expression of GAPDH. The P values comparing the expression of NDRG2 and c-MYC between the 
thyroid cancer and the adjacent normal tissues were below 0.05. (B) Analysis of NDRG2 expression using the different histo-
types and distant metastasis of thyroid cancer. There are four histotypes of thyroid cancers, including papillary carcinomas 
(PTC), follicular carcinomas (FTC), medullary carcinomas (MTC) and undifferentiated carcinomas (UTC). N in the bracket indi-
cates the numbers of each histotype. There were six patients with distal metastases and 29 with no metastasis. p > 0.05.BMC Cancer 2008, 8:303 http://www.biomedcentral.com/1471-2407/8/303
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nificantly reduced expression of Ndrg2 in thyroid cancers,
indicating the potential involvement of NDRG2 in the
processes of thyroid carcinoma formation. Real-time PCR
results demonstrated no correlation between NDRG2
expression and the patient's age or gender. There was also
no clear difference among the various types of thyroid
cancer. A slight decrease in NDRG2 was detected in the
thyroid adenoma tissues.
Our data indicated there was no correlation between
Ndrg2 and the metastasis of thyroid cancers. This result
was similar to the finding of Jung SH in breast cancer [25].
This group detected an inverse correlation between Ndrg2
expression and breast tumor size, but found no relation-
ship with auxiliary lymph node metastasis. As we did not
define the role of Ndrg2 in the metastasis of thyroid can-
cer, the mechanism of the involvement of Ndrg2 in cancer
needs to be more thoroughly examined in future studies.
We initially identified human NDRG2 as a candidate
tumor suppressor gene [10]. We found that the expression
of NDRG2 was significantly reduced in human glioblast-
oma tissues. Although the slight decrease of NDRG2
expression in thyroid adenomas was not significant, it
suggests that NDRG2 might be involved in mediating the
progression from thyroid adenoma to carcinoma. Further-
more, NDRG2 expression increased following the differ-
entiation of colon and dendritic cells [19]. Over-
expression of NDRG2 caused an inhibition of cell prolif-
eration and increased apoptosis in gastric cancer, through
Fas-mediated cell death [26]. NDRG2 may be involved in
tumor progression and overall survival of gastric cancer
patients.
Whether the down-regulation of NDRG2 in thyroid carci-
noma is a cause or a consequence remains presently
unclear. Further studies are needed to investigate how
NDRG2 is involved in the progression from normal thy-
roid tissue to thyroid cancer.
Conclusion
In conclusion, the protein and mRNA expression levels of
NDRG2 were significantly decreased in thyroid cancers
with c-Myc amplification. However, there were no signifi-
cant correlations of NDRG2 expression with gender, age,
the different histotypes of thyroid cancers, or distant
metastases. Our data provide novel insight into the
important role of NDRG2 in the development of thyroid
cancers. Further studies are needed to address whether the
down-regulation of NDRG2 is a cause or consequence of
the progression from the normal thyroid tissue to a carci-
noma.
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